The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with ...

US-based immuno-oncology company Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as Bavencio by its original developer Merck ...

A real-world study finds only modest uptake of maintenance avelumab following its July 2020 FDA approval for advanced or metastatic urothelial carcinoma, despite its proven survival benefit.

Intravenous drip Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma. Combination avelumab and axitinib has shown ...

The decision is welcomed as avelumab is the first and only monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic UC who are progression-free ...

As a brief background, JAVELIN Bladder 100 is a randomized phase III trial evaluating the use of maintenance immune checkpoint inhibitor avelumab in patients with unresectable locally advanced or ...

Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults. A table of NHS England interim treatment regimens gives possible alternative treatment ...

This randomized Phase II trial will be supported by a continuing collaboration with the alliance of Merck KGaA, Darmstadt, Germany, and Pfizer, which is supplying avelumab. Transgene retains all ...

Avelumab and cetuximab are both a type of targeted drug called a monoclonal antibody. They seek out cancer cells by targeting particular proteins on the cell surface. This trial was in 2 parts. The ...

A total of 805 patients received induction; 499 were randomly assigned to avelumab (n = 249) or continued chemotherapy (n = 250). Median OS was 10.4 months (95% CI, 9.1 to 12.0 months) versus 10.9 ...

Biomarkers of immune activity were linked with overall survival benefit to frontline maintenance avelumab in patients with advanced urothelial cancer, according to data presented at the ESMO Virtual ...